Enhancement of T cell recruitment and infiltration into tumours

Clinical and Experimental Immunology - Tập 178 Số 1 - Trang 1-8 - 2014
Christopher Oelkrug1,2, Judith M. Ramage1
1Academic Unit of Oncology, University of Nottingham, Nottingham, UK
2Cell Tharapy, Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany

Tóm tắt

SummaryStudies have documented that cancer patients with tumours which are highly infiltrated with cytotoxic T lymphocytes show enhanced survival rates. The ultimate goal of cancer immunotherapy is to elicit high-avidity tumour-specific T cells to migrate and kill malignant tumours. Novel antibody therapies such as ipilumimab (a cytotoxic T lymphocyte antigen-4 blocking antibody) show enhanced T cell infiltration into the tumour tissue and increased survival. More conventional therapies such as chemotherapy or anti-angiogenic therapy and recent therapies with oncolytic viruses have been shown to alter the tumour microenvironment and thereby lead to enhanced T cell infiltration. Understanding the mechanisms involved in the migration of high-avidity tumour-specific T cells into tumours will support and provide solutions for the optimization of therapeutic options in cancer immunotherapy.

Từ khóa


Tài liệu tham khảo

Chew, 2012, Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma, Gut, 61, 427, 10.1136/gutjnl-2011-300509

Dahlin, 2011, Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor, Mod Pathol, 24, 671, 10.1038/modpathol.2010.234

de la Cruz-Merino, 2011, Immune microenvironment in colorectal cancer: a new hallmark to change old paradigms, Clin Dev Immunol, 2011, 174149, 10.1155/2011/174149

Dutoit, 2001, Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity, Cancer Res, 61, 5850

Dutoit, 2002, Functional analysis of HLA-A*0201/Melan-A peptide multimer+ CD8+ T cells isolated from an HLA-A*, Cancer Immun, 2, 7

Dutoit, 2002, Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans, J Exp Med, 196, 207, 10.1084/jem.20020242

Marelli-Berg, 1999, Antigen recognition influences transendothelial migration of CD4+ T cells, J Immunol, 162, 696, 10.4049/jimmunol.162.2.696

Marelli-Berg, 2000, Activated murine endothelial cells have reduced immunogenicity for CD8+ T cells: a mechanism of immunoregulation?, J Immunol, 165, 4182, 10.4049/jimmunol.165.8.4182

Marelli-Berg, 2004, Cognate recognition of the endothelium induces HY-specific CD8+ T-lymphocyte transendothelial migration (diapedesis) in vivo, Blood, 103, 3111, 10.1182/blood-2003-08-2717

Marelli-Berg, 2004, Antigen presentation by the endothelium: a green light for antigen-specific T cell trafficking?, Immunol Lett, 93, 109, 10.1016/j.imlet.2004.03.014

Marelli-Berg, 2008, The highway code of T cell trafficking, J Pathol, 214, 179, 10.1002/path.2269

Marelli-Berg, 2010, Memory T-cell trafficking: new directions for busy commuters, Immunology, 130, 158, 10.1111/j.1365-2567.2010.03278.x

Rao, 2007, Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall, Circ Res, 101, 234, 10.1161/CIRCRESAHA.107.151860b

Weninger, 2002, Migration and differentiation of CD8+ T cells, Immunol Rev, 186, 221, 10.1034/j.1600-065X.2002.18618.x

Vianello, 2005, Fugetaxis: active movement of leukocytes away from a chemokinetic agent, J Mol Med (Berl), 83, 752, 10.1007/s00109-005-0675-z

Hamann, 2000, T-cell trafficking into sites of inflammation, Rheumatology (Oxf), 39, 696, 10.1093/rheumatology/39.7.696

Jaafar, 2009, Correlation of CXCL12 expression and FoxP3+ cell infiltration with human papillomavirus infection and clinicopathological progression of cervical cancer, Am J Pathol, 175, 1525, 10.2353/ajpath.2009.090295

Molon, 2011, Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells, J Exp Med, 208, 1949, 10.1084/jem.20101956

Lukacs, 2002, AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity, Am J Pathol, 160, 1353, 10.1016/S0002-9440(10)62562-X

Ben-Baruch, 2008, Organ selectivity in metastasis: regulation by chemokines and their receptors, Clin Exp Metastasis, 25, 345, 10.1007/s10585-007-9097-3

Curiel, 2004, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival, Nat Med, 10, 942, 10.1038/nm1093

Bailey, 2007, Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer, Clin Exp Metastasis, 24, 121, 10.1007/s10585-007-9060-3

Harlin, 2009, Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment, Cancer Res, 69, 3077, 10.1158/0008-5472.CAN-08-2281

Hong, 2011, Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control, Cancer Res, 71, 6997, 10.1158/0008-5472.CAN-11-1466

Hojo, 2007, High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer, Cancer Res, 67, 4725, 10.1158/0008-5472.CAN-06-3424

Poznansky, 2000, Active movement of T cells away from a chemokine, Nat Med, 6, 543, 10.1038/75022

Kryczek, 2007, Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis, Am J Physiol Cell Physiol, 292, C987, 10.1152/ajpcell.00406.2006

Schimanski, 2008, Chemokine receptor CXCR4-prognostic factor for gastrointestinal tumors, World J Gastroenterol, 14, 4721, 10.3748/wjg.14.4721

Yoshitake, 2008, Expression of SDF-1 alpha and nuclear CXCR4 predicts lymph node metastasis in colorectal cancer, Br J Cancer, 98, 1682, 10.1038/sj.bjc.6604363

Popple, 2012, The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer, Br J Cancer, 106, 1306, 10.1038/bjc.2012.49

Nardin, 2011, Dacarbazine promotes stromal remodeling and lymphocyte infiltration in cutaneous melanoma lesions, J Invest Dermatol, 131, 1896, 10.1038/jid.2011.128

Soriano, 2011, Metronomic cyclophosphamide and methotrexate chemotherapy combined with 1E10 anti-idiotype vaccine in metastatic breast cancer, Int J Breast Cancer, 2011, 710292, 10.4061/2011/710292

Demaria, 2001, Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy, Clin Cancer Res, 7, 3025

Antonia, 2006, Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer, Clin Cancer Res, 12, 878, 10.1158/1078-0432.CCR-05-2013

Alizadeh, 2014, Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer, Cancer Res, 74, 104, 10.1158/0008-5472.CAN-13-1545

Machiels, 2001, Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice, Cancer Res, 61, 3689

Martinet, 2011, Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer, Cancer Res, 71, 5678, 10.1158/0008-5472.CAN-11-0431

Hindley, 2012, T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion, Cancer Res, 72, 5473, 10.1158/0008-5472.CAN-12-1912

Weiss, 2012, Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells, PLOS ONE, 7, e31962, 10.1371/journal.pone.0031962

Li, 2010, Efficient Treg depletion induces T-cell infiltration and rejection of large tumors, Eur J Immunol, 40, 3325, 10.1002/eji.201041093

Roselli, 2013, Effects of conventional therapeutic interventions on the number and function of regulatory T cells, Oncoimmunology, 2, e27025, 10.4161/onci.27025

Datta, 2006, Differential effects of immunosuppressive drugs on T-cell motility, Am J Transplant, 6, 2871, 10.1111/j.1600-6143.2006.01553.x

Devaud, 2013, Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy, Oncoimmunology, 2, e25961, 10.4161/onci.25961

Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466

Huang, 2011, CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans, Clin Cancer Res, 17, 4101, 10.1158/1078-0432.CCR-11-0407

Simpson, 2013, Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma, J Exp Med, 210, 1695, 10.1084/jem.20130579

Peng, 2012, PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines, Cancer Res, 72, 5209, 10.1158/0008-5472.CAN-12-1187

Wu, 2012, CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma, Mol Cancer Ther, 11, 1809, 10.1158/1535-7163.MCT-11-1014

Holmgaard, 2013, Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4, J Exp Med, 210, 1389, 10.1084/jem.20130066

Waitz, 2012, Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy, Cancer Res, 72, 430, 10.1158/0008-5472.CAN-11-1782

Dirkx, 2003, Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression, Cancer Res, 63, 2322

Dirkx, 2006, Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors, FASEB J, 20, 621, 10.1096/fj.05-4493com

Shrimali, 2010, Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer, Cancer Res, 70, 6171, 10.1158/0008-5472.CAN-10-0153

Mulligan, 2009, Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions, Hum Immunol, 70, 375, 10.1016/j.humimm.2009.01.014

Wilmott, 2012, Combined targeted therapy and immunotherapy in the treatment of advanced melanoma, Oncoimmunology, 1, 997, 10.4161/onci.19865

Liu, 2013, BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice, Clin Cancer Res, 19, 393, 10.1158/1078-0432.CCR-12-1626

Wong, 2010, Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response, J Clin Oncol, 28, 723, 10.1200/JCO.2009.24.0143

Lemay, 2012, Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine, Mol Ther, 20, 1791, 10.1038/mt.2012.128

Yu, 2014, T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy, Mol Ther, 22, 102, 10.1038/mt.2013.240

Clinical trial: Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma

Huang, 2011, CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans, Clin Cancer Res, 17, 4101, 10.1158/1078-0432.CCR-11-0407